7 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $75M | -$146M | 0.0% | -289.0% | -$174M | — | $129M |
| 2024 | $29M | -$163M | 0.0% | -1091.7% | -$187M | — | $156M |
| 2023 | $38M | -$146M | 0.0% | -623.8% | -$121M | — | $133M |
| 2022 | $485M | $159M | 0.0% | 44.6% | $207M | — | $387M |
| 2021 | $375M | $153M | 0.0% | 54.5% | $186M | — | $476M |
| 2020 | $233M | $119M | 0.0% | 66.9% | $13M | — | $594M |
| 2019 | $12M | -$2M | 0.0% | -35.5% | -$1M | — | — |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $8M | -$43M | 0.0% | -691.7% | -$37M | — | $77M |
| Dec '25 | $45M | -$9M | 0.0% | -63.7% | -$45M | — | $129M |
| Sep '25 | $9M | -$57M | 0.0% | -851.8% | -$62M | — | $83M |
| Jun '25 | $17M | -$35M | 0.0% | -290.2% | -$46M | — | $92M |
| Mar '25 | $4M | -$46M | 0.0% | -1479.6% | -$22M | — | $159M |
| Dec '24 | $5M | -$34M | 0.0% | -1440.7% | -$24M | — | $156M |
| Sep '24 | $7M | -$51M | 0.0% | -1439.4% | -$47M | — | $127M |
| Jun '24 | $7M | -$37M | 0.0% | -1276.2% | -$50M | — | $148M |
| Mar '24 | $10M | -$41M | 0.0% | -551.5% | -$66M | — | $124M |
| Dec '23 | $9M | -$47M | 0.0% | -719.6% | -$34M | — | $133M |
| Sep '23 | $7M | -$29M | 0.0% | -831.8% | -$20M | — | $172M |
| Jun '23 | $10M | -$31M | 0.0% | -511.0% | -$7M | — | $180M |
| Mar '23 | $12M | -$40M | 0.0% | -532.1% | -$59M | — | $193M |
| Dec '22 | $22M | -$30M | 0.0% | -175.3% | $19M | — | $387M |
| Sep '22 | $101M | $27M | 0.0% | 37.2% | -$139M | — | $372M |
| Jun '22 | $46M | -$7M | 0.0% | -18.3% | $242M | — | $791M |
| Mar '22 | $317M | $169M | 0.0% | 71.1% | $86M | — | $546M |
| Dec '21 | $139M | $60M | 0.0% | 58.5% | -$26M | — | $476M |
| Sep '21 | $6M | -$21M | 0.0% | -510.1% | -$15M | — | $518M |
| Jun '21 | $28M | -$2M | 0.0% | -25.4% | $121M | — | $793M |
How the market has priced ABCL against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Abcellera Biologics Inc.'s revenue has declined 20.3% per year. These are computed facts, not advice.
As of FY2025, Abcellera Biologics Inc. reported — of total debt against $129M of cash.
In FY2025, gross margin was —, operating margin -289.0%, and net margin -194.9%.
As of Jun '26, Abcellera Biologics Inc. traded at a price-to-earnings ratio of about 11.0× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.